Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

The deal includes an undisclosed upfront payment from BMS, with GentiBio also in line to receive milestone payments of up to $1.9 billion, as well as royalties on any future sales. The partners ...

Evotec SE has announced substantial progress in its strategic research collaboration with Bristol Myers Squibb.

The firm reported a 6 percent decrease in Q1 2025 revenues to $11.2 billion compared to $11.87 billion last year.

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

Exscientia’s current clinical-stage pipeline consists of CDK7 inhibitor GTAEXS-617, which is co-owned with GT Apeiron, Evotec-partnered A2A receptor antagonist EXS-21546, and BMS-partnered PKC ...

And again, it helped us get the optimal molecule into patients faster. GEN Edge: And as for BMS’ pipeline, how many candidates are AI generated besides the HBF inducer? Plenge: 100% of our small ...

Bristol Myers Squibb (BMS) has agreed to acquire its longtime ... In 2023, the company divested its R&D pipeline – including cell therapy candidates for non-Hodgkin lymphoma (NHL), acute myeloid ...